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2Department of Medicine, Brigham and Women’s Hospital/Harvard Medical School, Boston, MA 02115, USAAbdominal aortic aneurysms (AAA) are associated with atherosclerosis, transmural degenerative processes, neovascular-
ization, decrease in content of vascular smooth muscle cells, and a chronic infiltration, mainly located in the outer aortic
wall.
The chronic infiltration consists mainly of macrophages, lymphocytes, and plasma cells. The dominant cells are Th2
restricted CD3C lymphocytes expressing interleukine 4, 5, 8, and 10, and tumor necrosis factor-a for regulation of the local
immune response. They also produce interferon-g and CD40 ligand to stimulate surrounding cells to produce matrix
metalloproteases and cysteine proteases for aortic matrix remodeling. The lymphocyte activation may be mediated by
microorganisms as well as autoantigens generated from vascular structural proteins, perhaps through molecular mimicry.
As in autoimmune diseases, the risk of AAA is increased by certain genotypes concerning human leucocyte antigen class II.
These types are also associated with increased aneurysmal inflammation indicating a genetic susceptibility to aortic
inflammation.
Chlamydia pneumoniae is often detected in AAA but the validity of the methods can be questioned, and two small
antibiotic trials have been disappointing. However, serum antibodies against C. pneumoniae have been associated with
AAA growth and cross-react with AAA wall proteins. Thus, immune responses mediated by microorganisms and
autoantigens may play a pivotal role in AAA pathogenesis.Keywords: Abdominal aortic aneurysm; Pathogenesis; Inflammation; Immunology; Immune response; Infection;
Autoimmune; Chlamydia.Introduction
The natural history of abdominal aortic aneurysms
(AAA) is dominated by inflammation,1 dilatation, and
terminal rupture. The pathogenesis has been a
mystery through decades—and still is. Even the
treatment remains controversial, and many believe a
pharmacological treatment of AAA is possible to
avoid surgery. If true, screening for AAA would
certainly become very cost effective.
Consequently, the present scientific interest in AAA
is probably at the highest level ever. However, the
combination of a high-pressured vessel located deep
in the body makes repeated biopsies impossible ining author. Jes S. Lindholt, MD, PhD, Department of
gery, Viborg Sygehus, P.O. Box 130, DK-8800 Viborg,
: jes.s.lindholt@sygehusviborg.dk
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theless, our knowledge about the fascinating patho-
genesis of AAA has increased rapidly the last few
years, especially concerning the key roles played by
the immune response.
Human AAAs are characterized by inflammation
with induction of intracellular and extracellular
inflammatory cytokines, expression of cell adhesion
molecules, increase of protease expression, and release
of reactive oxygen species. The most important
pathologic feature of human AAA is probably the
infiltration of inflammatory cells includingmonocytes,
lymphocytes, and plasma cells, mainly in the outer
part of the aorta, but also often beyond the aortic wall
into surrounding tissues.1 In addition to secrete
matrix-degrading proteases for vascular wall remo-
delling, these infiltrates are the main sources of
inflammatory cytokines, which are significantlyEur J Vasc Endovasc Surg 31, 453–463 (2006)
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regulating mesenchymal cell matrix metabolism,
endothelial cell growth and proliferation, lymphocyte
activation, antigen presenting cell (APC), major
histocompatibility (MHC) class II molecule
expression, vascular adhesion molecule expression,
and even matrix degrading protease expression of
surrounding cells.2 Logically, inhibition of such
infiltrate recruitment has been demonstrated to reduce
substantially the expansion rate of experimental
AAAs,3 and treatment with anti-inflammatory drugs
as steroid and cyclosporine reduce AAA-size in
animals,4 while macrolides and non-steroid anti-
inflammatory drugs reduce the aneurysmal growth
rate in human AAA.5,6
Thus, the understanding of the inflammatory
process in AAA may hold the solution for a low risk
pharmocological treatment, so a review was con-
ducted. This review is only based on AAA, and thus
it cannot be taken for sure that the features are
common for all aneurysms.Searching Strategy
Medline was searched for publications with the
keywords abdominal aortic aneurysms and immunity
or infection or autoimmune or autoimminty or chronic
inflammation including human as well as animal
studies. Reviews, non-English publications, and
papers without abstracts were omitted. In all, 401
papers were identified. More than half were irrelevant
clinical papers without hypothesized investigation of
the topics including a substantial number of case
reports. They were all omitted. Nevertheless, it
seemed irrational to cite all the rest, so representative
citations were selected, leaving mostly repetitive
studies and papers based on a small number of
participants uncited. A more complete list can be
achieved at the website ‘EJVESextra’.Histiological FindingsLymphocytes
The main cell population found in these inflammatory
infiltrates in AAAs is lymphocytes.
Using AAA tissue immunocytology analysis and
immunoblot analysis strategies, Schonbeck et al.
identified the majority of the lymphocytes as
T-helper(Th)-2-restricted CD3C T lymphocytes.Eur J Vasc Endovasc Surg Vol 31, May 2006Other lymphocytes such as B cells and Th1 cells
were relatively fewer.7
It is intriguing to understand why these cells are the
predominant population in AAAs and what these cells
contribute to the pathogenesis and how these cells are
regulated during the AAA development.
Th2-type lymphocytes in AAA lesions produce
interleukines (IL) such as IL-4, 5, 8, and 10.7 These
cytokines modulate the immune response by attrac-
tion of other inflammatory cells, stimulate further T
cell cytokine production, and neovascularization—all
factors amplifying the immune response (Fig. 1). In
addition to secrete cytokines, Th2 cells release Fas
ligand and Fas associated phosphotase-1 (FAP-1) to
regulate the apoptosis of vascular smooth muscle cells
(SMC) and Th1-restricted T lymphocytes.7,8 Other
non-lymphocytic cells can also be sensitized to Fas-
mediated cell death by this cytokine.9 This is probably
one of the mechanisms causing the reduced numbers
of Th1-type T lymphocytes and SMC, typically
detected in AAA lesions. Alternatively, Th2 cytokines
such as IL-4 also rescue Th2 lymphocytes, but not Th1
lymphocytes, from apoptosis in AAA.10
In addition to regulating the immune response and
cell apoptosis, these Th2-cells also produce interferon
(IFN)-g as well as CD40 ligand, especially when the
vascular wall is injured with microorganisms, surgery,
or even cigarette smoking.11–14 These cytokines
stimulate macrophages and monocytes to produce
matrix metalloproteinases (MMPs), such as MMP-3
and MMP-9, which are central proteases acquired for
vascular wall matrix remodelling.14
On the other hand, the most dominant Th2
cytokines are IL-4, 5 and 10, which suppress human
macrophage expression of MMP-9.15 While, the most
dominant Th1 cytokines are IFN-g, IL-2, IL-12, IL-15,
and IL-18. These cytokines are reported elevated in the
blood and aortic tissue of patients with AAAs,16 and
serum-IFN-g correlates with aneurysm progression
rate.17 It could suggest that Th2 immune responses
might serve to diminish aneurysmal degeneration.18
This is supported by animal studies showing that mice
lacking IL-4, IL-10 or CD4 develops larger elastase
induced aneurysms compared to common mice,
whereas no significant effect on AAAs has been
observed in mice with IFN-g deficiency. Others have
found that CD4-deficient mice do not develop
experimental aneurysms, unless IFN-g is admini-
strated. It could indicate that Th1-type immune
responses are essential in aneurysmal disease, and
shifting the cellular immune response from domina-
tion of Th1 cytokines to one favouring Th2 cytokines
could then in theory suppress aneurysmal
degeneration.19
Fig. 1. Major roles of Th2-lymphocytes in the chronic inflammation of the aneurysmal wall. Th2 lymphocyte activation by
antigen presenting cells such as macrophages, smooth muscle cells (SMC), and endothelial cells may depend on the function
of cathepsins. The activation causes secretion of cytokines. TNF-a and INF-g stimulates among others macrophages to
produce and secreteMMPs for matrix remodeling. Secretion of FAS-ligand and FAP-1 causes apoptosis of SMC and Th1 cells.
Further, inflammatory cells are recruited by TNF-a and IL-8, which also take part in stimulating neoangiogenesis. INF-g
stimulates cathepsin production for further Th2 activation, B-cell differentiation and Ig secretion.
Aortic Aneurysms and Immune Response 455Furthermore, histocompatibility-mismatched
aortas transplanted into IFN-g receptor-deficient
recipients causes an immune response dominated by
IL-4 and development of large aortic aneurysms—this
development could be prevented by administration of
anti-IL-4 blocking antibodies. Consequently, IL-4
specifically mediates an inflammatory process leading
to aneurysmal degeneration in this allograft model.20
In all, Th1 and Th2-restricted T lymphocyte
proliferation and activation seems very central in
regulating the immune response in AAA. It seems thatelevated local production of Th1 cytokines likely
serves to enhance macrophage expression of matrix-
degrading proteinases and thereby accelerate aneur-
ysmal degeneration, whereas Th2 cytokines appear to
exert responses that would tend to suppress macro-
phage MMP production and limit disease progression.Macrophages
Animal studies suggest macrophages are some of the
first inflammatory cells migrating to the developingEur J Vasc Endovasc Surg Vol 31, May 2006
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products.15 They may play a major role in the immune
response and matrix destruction due to their capacity
to secrete cytokines, elastase, and collagenases (Fig. 2).
The macrophage secretion of cytokines, as IL-1b, IL-6,
IL-8, and tumor necrosis factor (TNF)-a, recruits
inflammatory cells and stimulates cytokine pro-
duction, protease production, B-cell differentiation
and Ig secretion, cytotoxic T-cell differentiation, and
neovascularization. Besides their capacity to secrete
cytokines, their secretion of various proteases must beFig. 2.Major roles of macrophages in the chronic inflammation o
lymphocytes are activated possibly depending on cathepsins
secretion, secretion of IL-1b stimulates ICAM-1 presentation
differentiation and Ig secretion together with IL-6 secretion. In
stimulated by secretion of TNF-a.
Eur J Vasc Endovasc Surg Vol 31, May 2006considered very important in the natural history of
AAA, in particular MMP9, since it has been associated
with aneurysmal expansion and rupture (Fig. 2).21–23
The importance of the macrophages in the
pathogenesis of AAA is illustrated by animal
studies showing that the application of macrophages
and plasmin to the aorta is sufficient to cause
human-like aortic aneurysmal degradation without
further manipulation.24 Serum-plasmin has also
been reported to be one the most predictive factors
for aneurysmal growth.25f the aneurysmal wall. Acting as antigen presenting cell, Th2
. Cytokines from the activated Th2 cells stimulates MMP
for recruitment of inflammatory cells, and B-cell growth,
flammatory cells are attracted by IL-8. Neoangiogenesis are
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Apart from the luminal layer, endothelial cells are
present in AAA in large numbers due to the
neoangiogenesis observed throughout the media.
Their role may be even larger because inflammatory
cells expressing MMP as macrophages are mostly
localized in the surrounding areas of the microvessels,
where lymphocytes are also seen in large numbers. It
could be due to the capacity of the endothelium cell to
secrete IL-1b and IL-8, which stimulate ICAM-1
presentation for recruitment of additional inflamma-
tory cells, attract lymphocytes, stimulate endothelial
proliferation, and stimulate B-cell differentiation and
Ig secretion.
The proliferating endothelium also produces var-
ious matrix proteinases such as MMPs, as well as their
inhibitors—such as some of the tissue-inhibitors of
metalloproteinases (TIMP). Thus, the endothelium has
the capacity to break down the aortic matrix, but also
to control this degradation. Consequently, it has been
suggested that the magnitude of the neoangiogenesis
is associated with the severity of the aortic degra-
dation, and a histological study has demonstrated that
the degree of neovascularization correlates positively
with the degree of inflammation.26Fibroblasts
Fibroblasts are very frequent in the outer part of AAA,
and produce IL-6 which stimulates B-cell and cyto-
toxic T-cell differentiation together with several MMPs
in considerable amounts.27 In spite their capacity to
participate with a large pathogenic potential, very
little is known about their role.Immune Responses and T Cell Activation in AAA
Analysis of lymphoid areas in the adventitia from
AAA patients indicates the existence of T lymphocytes
and APCs, including B cells, dendritic cells, and
macrophages. These areas may locally serve as sites
for both cellular and humoral immune responses in
human AAAs.28 These interactions probably trigger T
cell activation to release the mentioned spectrum of
inflammatory cytokines, which participate in the
cellular and humoral immune response taking place
in AAAs (Fig. 2). Therefore, the mechanism of how the
T lymphocytes are activated during AAA develop-
ment becomes a key event in the AAA development
and essential to investigate.Several mechanisms have been implicated in the
regulation of the T lymphocyte activation in AAA. By
analyzing the serum components from AAA patients,
several laboratories have isolated AAA-specific anti-
gens that are most likely generated from vascular wall
matrix as well as microorganisms.29–33 Several micro-
organisms have been linked to aneurysm develop-
ment. Treponema pallidum infection, for example, may
lead to aortic aneurysm.34 Cytomegalovirus (CMV)
infection is common in inflammatory AAA although
this infection is asymptomatic.35 CMV virus is largely
co-localized with human leukocyte antigen (HLA)-DR
positive macrophages, fibroblasts, endothelial cells,
and lymphocytes.33
Other microbiological findings are reported in very
limited frequencies, and must probably be interpreted
as false positive findings due to contamination,
superinfections or coincidental findings.
Data from our laboratories indicate that Chlamydia
pneumoniae infection is associated with human AAA
progression. We have found a significant positive
correlation between IgA antibodies against C. pneu-
moniae and the aneurysmal expansion rate (rZ0.29,
PZ0.006)36 suggesting a possible immunologic role for
this microorganism in AAA. Further, Ozsvath et al. at
Tilsons laboratories have demonstrated that, in serum
components from AAA patients, there are several
antigens derived from microorganisms which are
closely related to normal vascular structural pro-
teins.37 IgG purified from AAA patients are immuno-
reactive to these autoantigens. The circulating self-
reactive autoantibodies are correlated with AAA size,
indicating an involvement of autoantigen in AAA
pathogenesis, possibly via T lymphocyte proliferation
and activation, although a clear mechanism and
consequence is missing and needs further
investigations.38
Clearly, more activated T cells are detected in AAA
lesions than control vessels. T cell activation has been
associated not only with AAA lesion levels but also
AAA lesion repairs. In patients undergoing AAA
repairs, different repair mechanisms lead to different
levels of T cell activation. By measuring peripheral
blood circulating T cell, aortic aneurysm-wall T cell,
and even perianeurysmal T cell phenotypes, several
groups have demonstrated that AAA endovascular
repair, which produces less tissue trauma, has much
less post-operative T cell activation than those of
conventional open surgery AAA repair.39,40 Flow
cytometry analysis indicates that the numbers of
activated T lymphocytes are associated with the
degree of vascular wall operative injury.40,41 A recent
study also demonstrated that different surgical trau-
mas altered the Th1/Th2 cell balance differently.Eur J Vasc Endovasc Surg Vol 31, May 2006
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patients underwent conventional infrarenal aortic
aneurysm repair than those who underwent endovas-
cular repair,42 correlating with the levels of active T
cells.
It can, therefore, be speculated that T lymphocyte
activation plays a key role in the AAA pathogenesis
and, consequently, that inhibition of T cell activation
may reduce AAA formation and progression.Chronic Infection in Aortic Aneurysms?
As mentioned, several microorganisms have been
linked to human AAA etiology. At present, C.
pneumoniae seems to be the major target for intensive
research. Although we currently do not have direct
evidence to support an etiologic role for C. pneumoniae
in AAA, presence of antibodies against C. pneumoniae
(Ig–Cp) has been associated with the expansion of
AAA.43–45 Further, C. pneumoniae has been demon-
strated in AAA by a variety of tests, including
immunohistochemical staining, enzyme-linked immu-
nosorbent assay, polymerase chain reaction (PCR),
electron microscopy, and culture (Table 1).45–50
The PCR tests were believed to be more sensitive
than the other methods for direct detection. However,
for validation, Apfalter et al. showed that the results of
attempts to detect intravascular C. pneumoniae DNA
varied in accordance between 0 and 100% among the
different laboratories. Further, several of the partici-
pating laboratories reported positive findings in theTable 1. Studies concerning Chlamydia pneumoniae and abdominal a
Reference Method Patients/
Lindholt43 Serological cohort study 112
Lindholt44 Serological cohort study 99
Petersen46 PCR 40/40
Lindholt47 PCR 20/0
Juvonen48 IHC, PCR, EM, culture 12/3
Blasi49 PCR 51/0
Ong50 IHC 25/6
Cheuck17 PCR 16C30/1
Vammen5 RCT: 300 mg roxithromycin for
28 days versus placebo
45/47
Mosorin53 RCT: doxycycline 150 mg daily for 3
months versus placebo
17/15
Scott (Chichester) RCT: 300 mg azithromycin for
28 days versus placebo
50/50
CP, antibodies against Chlamydia pneumoniae; IHC, immunohistochemis
randomized clinical controlled trial.
Eur J Vasc Endovasc Surg Vol 31, May 2006negative controls.51 This may explain, in part, the
reported poor correlation between demonstrating
present C. pneumoniae DNA/antigen in AAA or
atherosclerotic plaques and serum Ig–Cp.32,52,53
Regardless of the more sensitive PCR-test, immu-
nohistochemical staining apparently demonstrates
more positive results for C. pneumoniae than DNA-
based PCR techniques, and the results have a very
poor accordance with PCR-findings.45 An explanation
could be that the staining is too unspecific; we have
earlier demonstrated that Ig–Cp used for immunohis-
tochemical staining does not react on present chlamy-
dial protein in AAA-walls but cross-reacts with other
vascular contents of AAA.54
Finally, intervention trials with macrolides seem
only to have transient benefit, if any, but the trials
concerning AAA are few and small (Table 1).5,53,55
Nevertheless, similar but much larger intervention
studies concerning ischemic heart disease show the
same tendency for a short transient benefit, if any.45
This transient benefit could easily be caused by
the well-known anti-inflammatory effect of
macrolides.56
Finally, it must be questioned whether C. pneumo-
niae is present in AAA at all. However, Tambiah et al.
showed in an animal model that C. pneumoniae
stimulates the influx of macrophages and dilatation
of the abdominal aorta.57 Ig–Cp are associated with
AAA, and we have demonstrated that such antibodies
correlate positively with aneurymal growth rates in
Danish as well as British populations of patients with
small AAA.45ortic aneurysms
controls Results
Increased expansion rate in AAA-patients with CP–IgA
O20, and the level of IgG were predictive for cases
expanding to operation recommendable sizes
Positive correlation between CP-IgG and the aneur-
ysmal growth rate
35% positive AAA patients, 5% positive controls
0% positive
100% positive, no positive controls. No cultured
51% positive
56% positive in AAA patients, none in controls
9 16/16 (100%) positive in ruptured cases, 22/33 (73%) in
asymptomatic cases, and 2/19 (11%) in controls
44% reduced expansion rate the 1st year in the group
treated with macrolide compared with placebo. No
effect during the 2nd year
0–6 months: no significant difference in expansion rate
6–12 months: significant difference in expansion rate
12–18 months: significant difference in expansion rate
Ongoing
try; PCR, polymerase chain reaction; EM, electron microscopy; RCT,
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patients, applied them to homogenized AAA-walls
and performed 2D-gel electrophoreses of materials.
No sign of C. pneumoniae outer membrane protein was
observed, but the purified antibodies constantly cross-
reacted with components of the AAA wall com-
ponents, especially the heavy chain of human
immunoglobulin. The only known human antibodies
binding to the heavy chain of human immunoglobulin
are rheumafactors, which are strongly associated with
autoimmune diseases. This finding combined with the
reported positive correlation between antibodies
against C. pneumoniae with aneurysmal expansion
rate could indicate an important involvement of
autoantigens in progression of AAA.58An Autoimmune Disease?
The specificity of the immune response in AAAs
remains unclear, as B lymphocytes derived from
AAAs exhibit an unrestricted repertoire of immuno-
globulin,59 and a similar T cell polyclonal response,60
as well as presence of activated memory cells.61 These
results suggest an autoimmune disease and existence
of a cellular immune response in AAA. The possibility
that AAA is an autoimmune disease is further
supported by histological examinations of AAA-
walls, which show chronic inflammation, Russells
bodies (as in the autoimmune disease—Hasimoto’s
thyroiditis62–64), elevated cytokines that activate pro-
teolysis,65 and substantially increased amounts of
autoantibodies compared with aortic occlusive
diseases and normal aortae.63 Furthermore, the
prevalence of autoimmune diseases has been
described increased cases with inflammatory
aneurysms.67
Like other autoimmune diseases, AAA suscepti-
bility is associated with particular human leukocyte
antigens (HLA) molecules. For instance, specific
alleles of HLA-DR2, but not HLA-DQ3 are frequently
observed in AAA, similar to what is reported in
rheumatoid arthritis and multiple sclerosis.60–70 Ras-
mussen et al. showed that the B1(*)02 and B1(*)04
alleles in HLA were associated with more than a
doubled risk of AAA, and that the degree of
inflammation quantified histologically was associated
with these tissue types. These results suggest the HLA
class II immune response genes possess both disease-
modulation and disease-risk properties, and thus that
some kind of a genetic susceptibility to aortic
inflammation exists.71 These findings could have an
important clinical impact because if these genotypes
affect aneurysmal expansion rates and risk of rupture,they could provide us with a valuable predictive tool
for the use of surveillance versus surgery.
AAA tissues also contain large amounts of
immunoglobulin protein, and IgG extracted from
human AAAs exhibits immunoreactivity with aortic
wall matrix proteins.72 This suggests that a humoral
(auto)immune response is a frequent occurrence in
AAAs. Recent work has led to identification of several
putative antigens that may be novel extracellular
matrix proteins associated with large arteries.31
What still remains mysterious is the finding of
autoantibodies, which recognize human proteins as
well as epitopes on frequent invading microorgan-
isms.72 Although the presentation of autoantigen and
the production of autoantibodies are acquired for Tcell
proliferation and activation, the actual resource of
autoantigens is still under investigation. For instance,
the aortic aneurysm antigenic protein-40 (AAAP40) is
a microfibril-associated glycoprotein and is artery-
specific antigenic protein. Protein-sequence homology
search indicates its similarity to all three fibrinogen
chains and a short sequence similarity to vitronectin.30
A puzzle waiting to be solved is how the individual
immune system recognizes both exogenous microor-
ganisms and its own human aortic-wall proteins. It has
been hypothesized that microorganisms and normal
aortic wall may share the same or similar epitopes,
which can be recognized and presented by B cells,
dendritic cells, macrophages, activated endothelium,
and even HLA-DRC SMC in AAAvia a process known
as ‘molecule mimicry’.73 The presence of C. pneumoniae
in the AAA walls is questioned at the moment, but
recurrent respiratory tract infections due to C.
pneumoniae are common and the following systemic
immune response could trigger or amplify a local
aortic immune response due to molecule mimicry
when age-related degenerative changes of the aorta
occur. Alternatively, immune responses against aortic
wall structural components may arise secondary to
long-standing inflammation and connective tissue
destruction, through proteolytic exposure of neoepi-
topes within matrix proteins.
Nevertheless, in conclusion, several autoantigens
including elastin fragment, interstitial collagen, and
oxidized LDL have been identified in patients with
AAA. Immunoglobulins recognizing such autoanti-
gens have been purified from patient serum
samples.37,38,72–76 All in all, the findings indicate that
autoimmunity plays a role in AAA progression and
perhaps development. The magnitude and exact role
is still unknown, however, the combination of the
correlation between aneurysmal progression rate and
antibodies against C. pneumoniae that also areEur J Vasc Endovasc Surg Vol 31, May 2006
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major role.Potential Immunomodulating Autoantigen-specific
T-cell Response Therapy
One alternative to regulate T cell activation is
controlling the APCs to present aneurysm-specific
antigens. Although, currently, we do not have any
evidence to prove this concept, several possibilities
exist. In AAA, macrophages, activated endothelium,
and HLA-DRC SMCs are the main APCs. A classic
mechanism of activating T helper cells involves
interaction of T helper cells and HLA DRC APCs
mediated by T cell surface CD4 molecules and APC
surface antigen associated MHC class II molecules.
During the process of antigen presentation, exogenous
antigens have to be processed into antigenic peptide
and presented by the MHC class II molecule via a
chaperon molecule known as invariant chain (Ii) to the
cell surface.77,78 Recent findings indicate a role for
cysteine proteases in regulating Ii chain processing. In
mice with deficient cathepsin L expression, CD4C T
helper cell maturation within the thymus is decreased
by up to 50%.79 Such down-regulated CD4C T cells
may impact the pathophysiology of vascular diseases
including atherosclerosis and AAA as both lesions
contain CD4C T cells as the predominant
lymphocytes.2,7
Cathepsin S, another mammalian elastase highly
expressed in both atherosclerosis and AAA, has also
been demonstrated to be essential for APCs to
properly present exogenous and autoantigens. In
mice and in cell cultures, inhibition or deficiency of
cathepsin S impairs Ii processing and leads to the
accumulation of incompletely processed Ii (Ii p10)
bound MHC class II molecules at the cell surfaces.80,81
Phenotypically, these mice show impaired immuno-
globulin isotype switching and decreased antibody
production, although T lymphocyte maturation is
unaffected. However, todate, no data have been
provided to show if such altered T cell maturation or
impaired APC antigen presentation have any impact
on AAA.
A few lines of indirect evidence may suggest a
potential role for these immune response-related
proteases in AAA pathogenesis. First, using AAA
tissue extracts in Western blot analyses, we detected
significantly higher amount of both cathepsins S82 and
L compared with normal aortae (Shi, unpublished
data). In contrast, the normal vessel walls contained
negligible levels of these enzymes. In addition, to
cause vascular extracellular matrix degradation, theseEur J Vasc Endovasc Surg Vol 31, May 2006enzymes may be required for AAA immune
responses. Inhibition of cysteine proteases by high
doses of LHVS (morpholinurea leucine-homopheny-
lalanine-vinylsulfone-phenyl, a small molecule
cysteine-protease inhibitor) leads to accumulation of
macrophage cell surface Ii p10/MHC class II
complexes in culture, and impaired pulmonary
eosinophilic responses and IgE production in a
mouse pulmonary hypersensitivity model.83 Given
the fact that macrophages are among APCs in AAA,
inhibition of cysteine proteases may affect macrophage
antigen presentation, impair immune responses and T
cell activations, and further reduce AAA lesion
growth. This is supported by clinical prospective
data showing a negative correlation between aneur-
ysmal growth rate and the systemic level of its major
inhibitor, cystatin C.84
Second, activated endothelium and HLA-DRC
SMCs are another two main APC populations. Both
endothelium and SMCs express MHC class II mol-
ecules when cells are stimulated with IFN-g, an
inflammatory cytokine released in AAA from either
infiltrated T cells or monocytes.2 Consistently, this
cytokine has been shown to regulate cysteine protease
expression in both human endothelium and SMCs
in vitro.85,86 In human atherosclerotic lesions, both
endothelium and SMCs show strong staining for
immunoreactive cathepsin S expression with coloca-
lized MHC class II positive SMC.82 Therefore, it is
plausible that cathepsin S may regulate MHC class IIC
EC and SMC antigen or autoantigen presentation in
AAA. Further, inhibition of cathepsin S activity has
been proven to be effective to regulate autoantigen
presentation in a mouse model of Sjogren syndrome, a
clinicopathologic entity resulting from lacrimal and
salivary gland immunologic destruction.87 Similar to
AAA, in addition to lymphocyte infiltration, organ-
specific autoantigen and autoantigen-specific T cell
responses play an essential role in Sjogrens Syndrome.
Inhibition of cathepsin S prevents such Tcell responses
and associated autoimmunity,87 suggesting a possi-
bility of regulating AAA by controlling cathepsin S
activity in modulating autoantigen-specific T cell
responses.Clinical Aspects
So far the clinical aspects of our knowledge of the
immune response in AAA are limited. The potentials
are prediction of the natural history of AAA concern-
ing expansion and rupture, and pharmacological
treatment to prevent need for AAA repair. However,
so far little is known.
Aortic Aneurysms and Immune Response 461Stimulated by the possibility of an infectious
pathogenesis, small intervention trials with macro-
lides have been performed but they only to have
transient benefit, if any (Table 1).5,53,55
However, this transient benefit could be due to the
known anti-inflammatory effect of macrolides. Conse-
quently, a long term trial with doxycycline treatment is
ongoing.88 Another indication of the potential of anti-
inflammatory effect was noticed by Franklin et al. in a
case–control study; the expansion rate of AAA in 15
patients taking non-steroidal anti-inflammatory drugs
were 1.5 mm annually compared to 3.2 mm/year in 63
patients not taking non-steroidal anti-inflammatory
drugs, PZ0.001.89 This comparison was done after the
observation that indomethacin abolished PGE2
secretion and significantly reduced IL-1b and IL-6
secretion in aneurysm explant cultures. However, as
IL-1b, IL-6, and IFN-g failed to show any correlation
with aneurysmal expansion rate in 50 cases of small
AAA, whereas TNF-a did with a correlation similar to
the best serological markers known at present (rZ
0.37).11Summary and Future Topics
Abdominal aortic aneurysms (AAA) are associated
with a chronic infiltration, mainly located in the outer
aortic wall. The dominant cells are Th2 restricted
CD3C lymphocytes that express different cytokines
essential for the regulation of the local immune
response and the secretion of matrix metalloproteases
(MMP) and cysteine proteases, all essential for
vascular wall matrix remodelling.
The presence of C. pneumoniae in AAA walls is
questioned, and two small antibiotic trials have been
disappointing. However, serum antibodies against C.
pneumoniae have been associated with AAA growth
and cross-react with AAA wall proteins. Thus, the
lymphocyte activation may be mediated by microor-
ganisms as well as autoantigens generated from
vascular structural proteins through molecule
mimicry. HLA studies have shown that some HLA
DR2 B1 alleles are associated with increased risk of
AAA and, when an AAA is present, with increased
aneurysmal inflammation. Recent studies suggest the
key enzyme in this antigen presentation could be
cathepsin C.
Investigations are in progress analyzing the
relationship between various known autoantibodies
and cases with AAA by comparison with controls, and
the correlation of these antibodies with aneurysmal
progression rates. Studies analyzing the association
between the predisposing HLA DR2 B1 alleles andexpansion rates and risk of rupture would be
welcome, since that information could provide us
with a immediate valuable predictive tool for the
selection between surveillance or surgery. Addition-
ally, investigations are now in progress to try to
confirm the role of cathepsin S by clinical data, but
intervention trials inhibiting cathepsin S in mouse
models of AAAwould be relevant.References
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